What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
Conclusion: When ECOG PS and hepatic reserve function permit, continuing LEN treatment beyond PD, especially in u-HCC patients showed HFSR during LEN treatment, might be a good therapeutic option, at least until a more effective drug as a postprogression treatment after LEN failure is developed.Liver Cancer
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Children | Hepatocellular Carcinoma | Liver | Liver Cancer | Skin | Urology & Nephrology